USE OF IMATINIB (GLIVEC, STI-571) TO INHIBIT BREAST CANCER RESISTANCE PROTEIN (BCRP)-MEDIATED RESISTANCE TO THERAPEUTIC AGENTS

摘要

The present invention relates to the use of imatinib of the following formula or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a cancer that expresses breast cancer resistant protein (BCRP) in a human subject in need of such a treatment.